The INNs and outs of antibody nonproprietary names

References

• WHO-INN: Guidelines on the use of International Nonproprietary Names (INNs) for pharmaceutical substances [Internet] 1997. Available from: http://apps.who.int/iris/bitstream/Q210665/63779/1/WHO_PHARM_S_NOM_1570.pdf
   Google Scholar
• WHO-INN: WHO Drug Information [Internet] 2009. Available from: http://www.who.int/medicines/publications/druginformation/issues/DrugInfo09_Vol23-3.pdf
   Google Scholar
• WHO-INN: International nonproprietary names (INN) for biological and biotechnological substances (a review) [Internet] 2011. Available from: http://www.who.int/medicines/services/inn/BioRev2011.pdf
   Google Scholar
• WHO-INN: International nonproprietary names (INN) for biological and biotechnological substances (a review) [Internet] 2014. Available from: http://www.who.int/medicines/services/inn/BioRev2014.pdf
   Google Scholar
• Wu TT, Kabat EA. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970; 132:211-50; PMID:5508247; http://dx.doi.org/10.1084/jem.132.2.211
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196:901-17; PMID:3681981; http://dx.doi.org/10.1016/0022-2836(87)90412-8
   PubMed Web of Science ®Google Scholar
• Lefranc M-P, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, Thouvenin-Contet V, Lefranc G. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003; 27:55-77; PMID:12477501; http://dx.doi.org/10.1016/S0145-305X(02)00039-3
   PubMed Web of Science ®Google Scholar
• Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215:403-10; PMID:2231712; http://dx.doi.org/10.1016/S0022-2836(05)80360-2
   PubMed Web of Science ®Google Scholar
• AMA: Monoclonal Antibody Rules.[Internet] Accessed 2015 Oct 2; Available from: http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council.page
   Google Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3-10; PMID:15848070; http://dx.doi.org/10.1016/j.ymeth.2005.01.001
   PubMed Web of Science ®Google Scholar
• Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010; 1:314-22; PMID:21487506; http://dx.doi.org/10.4161/self.1.4.13904
   PubMedGoogle Scholar
• Schellekens H. The immunogenicity of therapeutic proteins. Discov Med 2010; 9:560-4; PMID:20587346
   PubMed Web of Science ®Google Scholar
• Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-97; PMID:1748994; http://dx.doi.org/10.1016/0022-2836(91)90498-U
   PubMed Web of Science ®Google Scholar
• Lee C V, Liang W-C, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 2004; 340:1073-93; PMID:15236968; http://dx.doi.org/10.1016/j.jmb.2004.05.051
   PubMed Web of Science ®Google Scholar
• Rothe C, Urlinger S, Löhning C, Prassler J, Stark Y, Jäger U, Hubner B, Bardroff M, Pradel I, Boss M, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008; 376:1182-200; PMID:18191144; http://dx.doi.org/10.1016/j.jmb.2007.12.018
   PubMed Web of Science ®Google Scholar
• Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 2014; 5:445-70; PMID:23571156; http://dx.doi.org/10.4161/mabs.24218
   PubMed Web of Science ®Google Scholar
• Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng Y, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7:13-21; PMID:8075633; http://dx.doi.org/10.1038/ng0594-13
   PubMed Web of Science ®Google Scholar
• Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368:856-9; PMID:8159246; http://dx.doi.org/10.1038/368856a0
   PubMed Web of Science ®Google Scholar
• Fishwild DM, O'Donnell SL, Bengoechea T, Hudson D V, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14:845-51; PMID:9631008; http://dx.doi.org/10.1038/nbt0796-845
   PubMed Web of Science ®Google Scholar
• Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997; 15:146-56; PMID:9020839; http://dx.doi.org/10.1038/ng0297-146
   PubMed Web of Science ®Google Scholar
• Nicholson IC, Zou X, Popov A V, Cook GP, Corps EM, Humphries S, Ayling C, Goyenechea B, Xian J, Taussig MJ, et al. Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes. J Immunol 1999; 163:6898-906; PMID:10586092
   PubMed Web of Science ®Google Scholar
• Yamaura N, Makino M, Walsh LJ, Bruce AW, Choe BK. Production of monoclonal antibodies against prostatic acid phosphatase by in vitro immunization of human spleen cells. J Immunol Methods 1985; 84:105-16; PMID:2415632; http://dx.doi.org/10.1016/0022-1759(85)90419-3
   PubMed Web of Science ®Google Scholar
• Doenecke A, Winnacker E-L, Hallek M. Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and. Leukemia 1997; 11:1787-92; PMID:9324302; http://dx.doi.org/10.1038/sj.leu.2400781
   PubMed Web of Science ®Google Scholar
• Ainai A, Kawase T, Ida A, Maeda Y, Ohba H, Ikeda Y, Sato H, Takahashi M, Chiba J. Renewal of EBV-hybridoma method: efficient generation of recombinant fully human neutralizing IgG antibodies specific for tetanus toxin by use of tetroma cells. Hum Antibodies 2006; 15:139-54; PMID:17522436
   PubMedGoogle Scholar
• Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329:112-24; PMID:17996249; http://dx.doi.org/10.1016/j.jim.2007.09.017
   PubMed Web of Science ®Google Scholar
• Kwakkenbos MJ, Bakker AQ, van Helden PM, Wagner K, Yasuda E, Spits H, Beaumont T. Genetic manipulation of B cells for the isolation of rare therapeutic antibodies from the human repertoire. Methods 2014; 65:38-43; PMID:23867338; http://dx.doi.org/10.1016/j.ymeth.2013.07.002
   PubMed Web of Science ®Google Scholar
• Julien J-P, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 2013; 9:e1003342; PMID:23658524; http://dx.doi.org/10.1371/journal.ppat.1003342
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TYK, Pietzsch J, Fenyo D, Abadir A, Velinzon K, et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science 2011; 333:1633-7; PMID:21764753; http://dx.doi.org/10.1126/science.1207227
   PubMed Web of Science ®Google Scholar
• Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu R-B, Fu BZ, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153:126-38; PMID:23540694; http://dx.doi.org/10.1016/j.cell.2013.03.018
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland A M, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http://dx.doi.org/10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006; 55:717-27; PMID:16151804; http://dx.doi.org/10.1007/s00262-005-0058-x
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9; PMID:9377574
   PubMed Web of Science ®Google Scholar
• Chuntharapai A, Lai J, Huang X, Gibbs V, Kim KJ, Presta LG, Stewart TA. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 2001; 15:250-60; PMID:11594789; http://dx.doi.org/10.1006/cyto.2001.0934
   PubMed Web of Science ®Google Scholar
• Johnson S, Oliver C, Prince G A, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115
   PubMed Web of Science ®Google Scholar
• Li B, Wang H, Dai J, Ji J, Qian W, Zhang D, Hou S, Guo Y. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 2005; 116:487-98; PMID:16313362
   PubMed Web of Science ®Google Scholar
• Saldanha J. Molecular engineering i: humanisation strategies. In: Dübel S, Reichert JM, editors. Handbook of Therapeutic Antibodies. 2nd ed. Weinheim, Germany: Wiley-VCH Verlag GmbH; 2014
   Google Scholar
• Dall'Acqua WF, Damschroder MM, Zhang J, Woods RM, Widjaja L, Yu J, Wu H. Antibody humanization by framework shuffling. Methods 2005; 36:43-60; PMID:15848074; http://dx.doi.org/10.1016/j.ymeth.2005.01.005
   PubMedGoogle Scholar
• Lazar GA, Desjarlais JR, Jacinto J, Karki S, Hammond PW. A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol 2007; 44:1986-98; PMID:17079018; http://dx.doi.org/10.1016/j.molimm.2006.09.029
   PubMed Web of Science ®Google Scholar
• Holgate RGE, Weldon R, Jones TD, Baker MP. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity. PLoS One 2015; 10:e0138123; PMID:26372145; http://dx.doi.org/10.1371/journal.pone.0138123
   PubMed Web of Science ®Google Scholar
• Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S-B, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13:869-78; PMID:22884505; http://dx.doi.org/10.1016/S1470-2045(12)70329-7
   PubMed Web of Science ®Google Scholar
• Abhinandan KR, Martin ACR. Analyzing the “degree of humanness” of antibody sequences. J Mol Biol 2007; 369:852-62; PMID:17442342; http://dx.doi.org/10.1016/j.jmb.2007.02.100
   PubMed Web of Science ®Google Scholar
• MacCallum RM, Martin A C, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 1996; 262:732-45; PMID:8876650; http://dx.doi.org/10.1006/jmbi.1996.0548
   PubMed Web of Science ®Google Scholar
• Stave JW, Lindpaintner K. Antibody and antigen contact residues define epitope and paratope size and structure. J Immunol 2013; 191:1428-35; PMID:23797669; http://dx.doi.org/10.4049/jimmunol.1203198
   PubMed Web of Science ®Google Scholar
• Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487-99; PMID:1560463; http://dx.doi.org/10.1016/0022-2836(92)91010-M
   PubMed Web of Science ®Google Scholar
• McKinstry WJ, Polekhina G, Diefenbach-Jagger H, Ho PWM, Sato K, Onuma E, Gillespie MT, Martin TJ, Parker MW. Structural basis for antibody discrimination between two hormones that recognize the parathyroid hormone receptor. J Biol Chem 2009; 284:15557-63; PMID:19346515; http://dx.doi.org/10.1074/jbc.M900044200
   PubMed Web of Science ®Google Scholar
• Zhou T, Hamer DH, Hendrickson WA, Sattentau QJ, Kwong PD. Interfacial metal and antibody recognition. Proc Natl Acad Sci U S A 2005; 102:14575-80; PMID:16195378; http://dx.doi.org/10.1073/pnas.0507267102
   PubMed Web of Science ®Google Scholar
• Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18:2714-23; PMID:9504803; http://dx.doi.org/10.1002/elps.1150181505
   PubMed Web of Science ®Google Scholar